About Dupixent

Lorem ipsum dolor sit amet, probo tantas commune at mea, te est vidisse perfecto adipiscing, id tota admodum efficiendi has. Assum honestatis ne vim.

Mechanism of Action

Lorem ipsum dolor sit amet, probo tantas commune at mea, te est vidisse perfecto adipiscing, id tota admodum efficiendi has. Assum honestatis ne vim.

Dosing

Lorem ipsum dolor sit amet, probo tantas commune at mea, te est vidisse perfecto adipiscing, id tota admodum efficiendi has. Assum honestatis ne vim.

Access Dupixent

Lorem ipsum dolor sit amet, probo tantas commune at mea, te est vidisse perfecto adipiscing, id tota admodum efficiendi has. Assum honestatis ne vim.

Resources & Tools

Lorem ipsum dolor sit amet, probo tantas commune at mea, te est vidisse perfecto adipiscing, id tota admodum efficiendi has. Assum honestatis ne vim.

References

  1. Australian Approved Product Information for Dupixent (dupilumab). 1 April 2021.
  2. Boguniewicz et al. Ann Allergy Asthma Immunol 2018: 120: 10–22.
  3. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.
  4. Blauvelt A et al. Lancet 2017; 389: 2287–2303.
  5. De Bruin-Weller M et al. Presentation at 27th EADV Congress; 2018; September 12-16; Paris, France.
  6. Simpson EL et al. JAMA Dermatol 2020; 156(1): 44–56.
  7. Wollenberg A et al. Br J Dermatol 2020; 182: 1120–1135.
  8. Siegfried EC et al. Poster presented at the 19th Annual Meeting of the European Society for Pediatric Dermatology; May 2–4, 2019; Dubrovnik, Croatia.